18F-FDG PET Imaging of Myocardial Viability in an Experienced Center with Access to 18F-FDG and Integration with Clinical Management Teams: The Ottawa-FIVE Substudy of the PARR 2 Trial

被引:109
|
作者
Abraham, Arun [1 ,2 ]
Nichol, Graham [3 ]
Williams, Kathryn A. [1 ,2 ]
Guo, Ann [1 ,2 ]
deKemp, Robert A. [1 ,2 ]
Garrard, Linda [1 ,2 ]
Davies, Ross A. [1 ,2 ]
Duchesne, Lloyd [1 ,2 ]
Haddad, Haissam [1 ,2 ]
Chow, Benjamin [1 ,2 ]
DaSilva, Jean [1 ,2 ]
Beanlands, Rob S. B. [1 ,2 ]
机构
[1] Univ Ottawa, Inst Heart, Natl Cardiac PET Ctr, Ottawa, ON K1Y 4W7, Canada
[2] Univ Ottawa, Inst Heart, Div Cardiol, Cardiovasc Res Methods Ctr, Ottawa, ON K1Y 4W7, Canada
[3] Univ Washington, Harborview Ctr Prehosp Emergency Care, Seattle, WA 98195 USA
关键词
cardiology (clinical); PET; fluorodeoxyglucose; LV dysfunction; viability; LEFT-VENTRICULAR DYSFUNCTION; POSITRON-EMISSION-TOMOGRAPHY; CORONARY-ARTERY-DISEASE; RANDOMIZED-TRIALS; REVASCULARIZATION; PROGNOSIS; MORTALITY; SUBGROUP; INFARCTION; SURVIVAL;
D O I
10.2967/jnumed.109.065938
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
F-18-FDG PET may assist decision making in ischemic cardiomyopathy. The PET and Recovery Following Revascularization (PARR 2) trial demonstrated a trend toward beneficial outcomes with PET-assisted management. The substudy of PARR 2 that we call Ottawa-FIVE, described here, was a post hoc analysis to determine the benefit of PET in a center with experience, ready access to F-18-FDG, and integration with clinical teams. Methods: Included were patients with left ventricular dysfunction and suspected coronary artery disease being considered for revascularization. The patients had been randomized in PARR 2 to PET-assisted management (group 1) or standard care (group 2) and had been enrolled in Ottawa after August 1, 2002 (the date that on-site F-18-FDG was initiated) (n = 111). The primary outcome was the composite endpoint of cardiac death, myocardial infarction, or cardiac rehospitalization within 1 y. Data were compared with the rest of PARR 2 (PET-assisted management [group 3] or standard care [group 4]). Results: In the Ottawa-FIVE subgroup of PARR 2, the cumulative proportion of patients experiencing the composite event was 19% (group 1), versus 41% (group 2). Multivariable Cox proportional hazards regression showed a benefit for the PET-assisted strategy (hazard ratio, 0.34; 95% confidence interval, 0.16-0.72; P = 0.005). Compared with other patients in PARR 2, Ottawa-FIVE patients had a lower ejection fraction (25% +/- 7% vs. 27% +/- 8%, P = 0.04), were more often female (24% vs. 13%, P = 0.006), tended to be older (64 +/- 10 y vs. 62 +/- 10 y, P = 0.07), and had less previous coronary artery bypass grafting (13% vs. 21%, P = 0.07). For patients in the rest of PARR 2, there was no significant difference in events between groups 3 and 4. The observed effect of F-18-FDG PET-assisted management in the 4 groups in the context of adjusted survival curves demonstrated a significant interaction (P = 0.016). Comparisons of the 2 arms in Ottawa-FIVE to the 2 arms in the rest of PARR 2 demonstrated a trend toward significance (standard care, P = 0.145; PET-assisted management, P = 0.057). Conclusion: In this post hoc group analysis, a significant reduction in cardiac events was observed in patients with F-18-FDG PET-assisted management, compared with patients who received standard care. The results suggest that outcome may be benefited using F-18-FDG PET in an experienced center with ready access to F-18-FDG and integration with imaging, heart failure, and revascularization teams.
引用
收藏
页码:567 / 574
页数:8
相关论文
共 50 条
  • [41] 18F-FDG PET/CT Imaging of Adrenal Liposarcoma
    Wang, Rang
    Fan, Qiuping
    Tian, Rong
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (07) : 570 - 571
  • [42] 18F-FDG PET Imaging Utilization in the National Lung Screening Trial
    Nair, Viswam S.
    Sundaram, Vandana
    Gould, Michael K.
    Gambhir, Sanjiv S.
    Desai, Manisha
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S396 - S397
  • [43] Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy
    Lin, Frank I.
    Rao, Jyotsna E.
    Mittra, Erik S.
    Nallapareddy, Kavitha
    Chengapa, Alka
    Dick, David W.
    Gambhir, Sanjiv Sam
    Iagaru, Andrei
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (02) : 262 - 270
  • [44] Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy
    Frank I. Lin
    Jyotsna E. Rao
    Erik S. Mittra
    Kavitha Nallapareddy
    Alka Chengapa
    David W. Dick
    Sanjiv Sam Gambhir
    Andrei Iagaru
    European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 262 - 270
  • [45] Imaging in myositis: MRI or 18F-FDG PET/CT?
    Ufuk İlgen
    Hakan Emmungil
    Clinical Rheumatology, 2022, 41 : 2253 - 2254
  • [46] 18F-FDG PET/CT imaging of testicular tumours
    Ambrosini, V.
    Ceci, F.
    Nicolini, S.
    Allegri, V.
    Nanni, C.
    Castellucci, P.
    Caroli, P.
    Fantini, L.
    Rubello, D.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S328 - S328
  • [47] 18F-FDG PET/CT imaging in tendon xanthomatosis
    Dae-Weung Kim
    Chang-Guhn Kim
    Soon-Ah Park
    Young Cheon Na
    European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35 : 1403 - 1404
  • [48] 18F-FDG PET imaging of progressive massive fibrosis
    Chung, Soo Yoon
    Lee, Jae Hoon
    Kim, Tae Hoon
    Kim, Sang Jin
    Kim, Hyung Joong
    Ryu, Young Hoon
    ANNALS OF NUCLEAR MEDICINE, 2010, 24 (01) : 21 - 27
  • [49] Early clinical experience and impact of 18F-FDG PET
    Gutte, H
    Hojgaard, L
    Kjær, A
    NUCLEAR MEDICINE COMMUNICATIONS, 2005, 26 (11) : 989 - 994
  • [50] Prognostic Implications of Imaging-Based Bone Marrow Assessment in Lymphoma: 18F-FDG PET, MR Imaging, or 18F-FDG PET/MR Imaging?
    Adams, Hugo J. A.
    Kwee, Thomas C.
    Nievelstein, Rutger A. J.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (11) : 2017 - 2018